Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5% ...

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Recent health news highlights Germany's Merck's acquisition talks with SpringWorks, U.S. Justice Department's disbanding of a ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...